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http://dx.doi.org/10.1016/j.stemcr.2017.01.026SUMMARYReprogramming of somatic cells into induced pluripotent stem cells (iPSCs) is accompanied bymorphological, functional, andmetabolic
alterations before acquisition of full pluripotency. Although the genome-wide effects of the reprogramming factors on gene expression
are well documented, precise mechanisms by which gene expression changes evoke phenotypic responses remain to be determined. We
used a Sendai virus-based system that permits reprogramming to progress in a strictly KLF4-dependent manner to screen for KLF4
target genes that are critical for the progression of reprogramming. The screening identified Tcl1 as a critical target gene that directs
the metabolic shift from oxidative phosphorylation to glycolysis. KLF4-induced TCL1 employs a two-pronged mechanism, whereby
TCL1 activates AKT to enhance glycolysis and counteracts PnPase to diminish oxidative phosphorylation. These regulatory mechanisms
described here highlight a central role for a reprogramming factor in orchestrating the metabolic shift toward the acquisition of plurip-
otency during iPSC generation.INTRODUCTION
Forced expression of OCT4, SOX2, KLF4, and c-MYC or
other combinations of reprogramming factors reprogram
somatic cells into induced pluripotent stem cells (iPSCs),
which attract much attention for their potential applica-
tions in regenerative medicine and drug development, as
well as for understanding how cells specify their fate during
reprogramming and normal development (Stadtfeld and
Hochedlinger, 2010; Takahashi and Yamanaka, 2016). Cells
that undergo reprogramming progress through distinct
stages, which can be distinguished by the expression of
THY1, alkaline phosphatase (AP), and SSEA1 (Polo et al.,
2012), initially losing somatic cell characteristics before
acquiring full pluripotency. Reprogramming factors, in
general, are transcription factors that alter gene expres-
sion and epigenetic status, which ultimately specify the
cell fate (Theunissen and Jaenisch, 2014). Therefore,
genome-wide analyses of gene expression and epigenetic
status provide comprehensive views on the mechanism
of reprogramming.
In addition to alterations in gene expression and epige-
netic status, cells undergo metabolic changes during re-
programming (Folmes et al., 2011; Samavarchi-Tehrani
et al., 2010). Embryonic stem cells (ESCs), which originally
comprise the inner cell mass, reside in the low-oxygen
environment (Fischer and Bavister, 1993) and have few
small mitochondria (Cho et al., 2006; St John et al.,
2005), utilizing glycolysis as a main source of ATP produc-Stem Cell
This is an open access article under the Ction (Xu et al., 2013). By contrast, differentiated somatic
cells largely depend on oxidative phosphorylation inmito-
chondria for efficient ATP production (DeBerardinis et al.,
2008). Thus, somatic cell reprogramming by necessity
entails a metabolic shift from oxidative phosphorylation
to glycolysis, which has been corroborated by recent
studies (Folmes et al., 2011; Prigione et al., 2010). Indeed,
deliberate acceleration of glycolysis or inhibition of oxida-
tive phosphorylation increases the reprogramming effi-
ciency (Prigione et al., 2014). Furthermore, enhanced
glycolysis produces higher amounts of metabolic interme-
diates that are used as cofactors by chromatin-modifying
enzymes (Moussaieff et al., 2015). Thus, themetabolic shift
and epigenetic regulation, both initiated by the reprogram-
ming factors, are likely to concur during the reprogram-
ming process. However, the molecular mechanisms by
which the reprogramming factors initiate and execute the
metabolic shift remains less well known.
We developed a unique gene transfer system termed
SeVdp (Sendai virus defective and persistent) vector, which
stably expresses multiple genes from a single vector with a
relatively constant stoichiometry without integrating into
the host cell genome (Nishimura et al., 2011). An SeVdp-
based vector, SeVdp(KOSM), which harbors the four Yama-
naka factors, generates iPSCsefficiently fromvarious sources
of somatic cells (Kyttala et al., 2016;Matsumotoet al., 2016).
Modifying SeVdp(KOSM), we devised SeVdp(fK-OSM) that
expresses KLF4 tagged with a destabilizing domain (DD)
(Banaszynski et al., 2006), the expression level of whichReports j Vol. 8 j 787–801 j March 14, 2017 j ª 2017 The Author(s). 787
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
can be manipulated by a small molecule, Shield1. In
the SeVdp(fK-OSM)-infected cells, the KLF4 level, reduced
to 30% by the DD, is readily restored to its original level
by the addition of 100 nM Shield1. Reprogramming with
SeVdp(fK-OSM) at a defined KLF4 level generates partially
reprogrammed iPSCs, termed paused iPSCs, which have
stalled at a specific intermediate stage but nonetheless
resume reprogramming toward full pluripotency once the
KLF4 level is restored by increased Shield1 (Nishimura
et al., 2014). Because the SeVdp(fK-OSM)-based system,
named the SeVdp-based stage-specific reprogramming sys-
tem (3S reprogramming system), allows reprogramming to
progress strictly in a KLF4-dependent manner, the system
enables us to analyze the role for KLF4 in a gene regulatory
network,whichmayoccur only transiently during the com-
plex process of reprogramming.
In this article, we searched for genes that are induced
by KLF4 in a dose-dependent manner and identified Tcl1
as its direct target. KLF4 induces Tcl1 transcription during
reprogramming via direct binding to its enhancer and pro-
moter regions, concurrently changing repressive histone
marks into active ones at the Tcl1 promoter. TCL1 induced
by KLF4 activates AKT to enhance glycolysis and inhibits
mitochondrial polynucleotide phosphorylase (PnPase) to
suppress oxidative phosphorylation. Knockdown of Tcl1
expression not only eliminates the metabolic shift but
severely compromises the expression of Cdh1 and Rex1 as
well. Thus, KLF4-promoted metabolic shift concurs with
the acquisition of pluripotency and is essential for gener-
ating fully reprogrammed iPSCs.RESULTS
Identification of Key Target Genes of KLF4 during
Reprogramming
To gain insight into the physiological events that KLF4
regulates during reprogramming toward full pluripo-
tency, we selected for genes that are regulated by KLF4 in
a dose-dependent manner. We performed genome-wide
expression analyses of the paused iPSCs, iPSCs(Low-K)
and iPSCs(High-K). iPSCs(Low-K), generated by SeVdp(fK-
OSM) without Shield1, express a low level of KLF4 and are
THY1, AP+, SSEA1, and NANOG. iPSCs(High-K), gener-
ated by SeVdp(fK-OSM) with 100 nM Shield1, express a
high level of KLF4 and are THY1, AP+, SSEA1+, and
NANOG+ (Figure 1A) (Nishimura et al., 2014). The transi-
tion from iPSCs(Low-K) to iPSCs(High-K), based upon our
previous principal component analyses, corresponds to a
middle-to-late stage of reprogramming (Nishimura et al.,
2014). Comparison of these two datasets identified 152
genes that are highly expressed only in iPSCs(High-K),
which were further narrowed down to 115 genes by788 Stem Cell Reports j Vol. 8 j 787–801 j March 14, 2017the presence of direct KLF4 binding around their tran-
scriptional start sites in mouse ESCs (Chen et al., 2008)
(Figure 1B).
The reprogramming pathway toward pluripotency may
vary among different reprogramming systems (O’Malley
et al., 2013; Parchem et al., 2014). To enrich for genes
whose late-stage upregulation is shared among different re-
programming systems and is therefore universally impor-
tant, we referred to yet another database to select for genes
that are induced at a late stage (>9 days) of reprogramming
in a lentivirus-mediated secondary reprogramming system
(Polo et al., 2012) (Figure 1B). Among the selected ten
genes (Figure S1A), qRT-PCR showed that seven of them
(Apoc1, Dmtn, Foxh1, Mapt, Tcl1, Tmem8, and Rex1) ex-
hibited a late-stage upregulation during reprogramming
in our SeVdp(KOSM)-based system (Figures 1C and S1B).
Six of the genes (Apoc1, Dmtn, Foxh1, Tcl1, Tmem8, and
Rex1) were upregulated more or less proportionately to
the KLF4 level (Figures 1D and S1C).
To examine the relative importance of the six candidate
genes, we tested whether each gene could complement
the low level of KLF4 expressed from SeVdp(fK-OSM) for
reprogramming. Each candidate gene was transduced
into mouse embryonic fibroblasts (MEFs) by the MCsDYY1
retrovirus vector, which is refractory to silencing during
reprogramming due to mutations in the YY1 binding site
and primer binding site (Iba et al., 2003; Kitamura et al.,
2003). The MEFs expressing each candidate gene were
subsequently infected by SeVdp(fK-OSM), which, without
Shield1, generates only paused iPSCs(Low-K). Retrovirus-
mediated expression of only FOXH1 and TCL1 increased
the mRNA levels of early and late pluripotency mar-
kers (Cdh1 and Rex1, respectively) (Figure 2A) and
the number of SSEA1+ colonies (Figure S2A) similarly to
those by the retrovirus-mediated expression of KLF4 or in
iPSCs(High-K). TCL1 increased the mRNA levels of other
pluripotency markers (Fbxo15, Oct4, Esrrb, and Nanog) to
similar degrees by KLF4 (Figure S2B). Next, we tested if
each candidate gene, when expressed from the retrovirus,
resumes reprogramming of paused iPSC(Low-K) clones.
Paused iPSC(Low-K) clones were initially generated by
20 days of infection with SeVdp(fK-OSM) without Shield1
and subsequently transducedwith theMCsDYY1 retrovirus
vector expressing each candidate gene. The expression
levels of Cdh1 and Rex1 were increased significantly only
when TCL1 was expressed in paused iPSC(Low-K) clones
(Figure 2B). TCL1 also increased the number of SSEA1+ col-
onies (Figure S2C) and the mRNA levels of Fbxo15, Oct4,
Esrrb, and Nanog (Figure S2D). These results indicate that
Tcl1 is upregulated by KLF4 in a dose-dependent manner
and may be its key target critical for bypassing or resuming
the paused reprogramming caused by the low KLF4 level.
We then asked if Tcl1 was a major downstream KLF4 target
Figure 1. Screening of Downstream Tar-
gets of KLF4 Using the 3S-reprogramming
System
(A) Outline of generating iPSCs(Low-K)
and iPSCs(High-K) in the 3S-reprogramming
system and their characteristics.
(B) Flowchart of the screening. Genome-
wide gene expression datasets (Nishimura
et al., 2014) were used to select 152 genes
that are expressed highly in iPSCs(High-K),
but not in iPSCs(Low-K). Other two datasets
(Chen et al., 2008; Polo et al., 2012) were
also used to enrich genes whose expression
is regulated by KLF4 and induced in a late
stage of reprogramming.
(C) Changes in the mRNA expression level of
seven candidate genes as well as Cdh1 and
Nanog genes during iPSC generation. MEFs
were reprogrammed by SeVdp(KOSM) and
their mRNA levels were determined at days 0,
2, 6, 13, and 25. Data represent means ± SEM
of three independent experiments.
(D) KLF4 dose-dependent mRNA expression
of six candidate genes as well as Cdh1 and
Nanog genes. MEFs were reprogrammed for
27 days by SeVdp(fK-OSM) with 0, 10, 30, or
100 nM of Shield1, and their mRNA levels
were determined. Data represent means ±
SEM of three independent experiments.
See also Figure S1 and Table S1.gene that mediated the effects of KLF4 to promote re-
programming. The expression of TCL1 was first knocked
down by transducing a retrovirus that expresses small
hairpin RNA (shRNA) against the Tcl1 gene into MEFs,
which were then reprogrammed by SeVdp(fK-OSM) with
or without 100 nMShield1. The shRNA reduced the expres-
sion levels of both Cdh1 and Rex1 in iPSCs(High-K) almost
to those observed in iPSCs(Low-K) (Figure 2C), indicating
that Tcl1 is a major mediator of the KLF4 effects during
reprogramming.
To further confirm the effect of TCL1 on reprogramming,
we constructed a new SeVdp vector that expresses TCL1 in
addition to the four Yamanaka factors (SeVdp(fKiT-OSM))
(Figure 3A). Without Shield1, SeVdp(fKiT-OSM) expressed
KLF4 only at a low level, as in the case of SeVdp(fK-OSM)
(Figure 3B); however, SeVdp(fKiT-OSM) induced expres-
sion of pluripotency markers, Cdh1, Fbxo15, Oct4, and
Esrrb, at levels comparable with those by SeVdp(fK-OSM)
with 100 nM Shield1 (iPSCs(High-K)) or by SeVdp(KOSM)(Figure3C).Notably, SeVdp(fKiT-OSM)markedlyaugmented
the expression of the late reprogramming markers,
Rex1 and Nanog, to the levels even higher than those
by SeVdp(KOSM), a representative Sendai virus vector
that establishes fully reprogrammed iPSCs from various
somatic cells (Kyttala et al., 2016; Matsumoto et al.,
2016) (Figure 3C). Moreover, SeVdp(fKiT-OSM)-infected
cells showed earlier induction of NANOG protein than
SeVdp(KOSM)-infected ones (Figures 3D and 3E). The
effect of TCL1, however, was diminished when the
KLF4 level was increased by the addition of Shield1 (Fig-
ure S3A). TCL1 also facilitated the reprogramming of
MEFs by retrovirus-mediated gene transfer of the four
Yamanaka factors (Figures S3B and S3C). When trans-
planted into mice, the derived iPSC clone, from which
the SeVdp(fKiT-OSM) vector was removed by small inter-
fering RNA against the SeV L gene (Nishimura et al.,
2011), formed teratomas consisting of three germ layers
(Figure 3F), indicating that SeVdp(fKiT-OSM) generatesStem Cell Reports j Vol. 8 j 787–801 j March 14, 2017 789
Figure 2. TCL1 Enhances Reprogramming as a Downstream
Target of KLF4
(A) Cdh1 and Rex1mRNA levels in MEFs reprogrammed for30 days
by SeVdp(fK-OSM). Two days prior to the reprogramming, MEFs were
infected with a retrovirus expressing each candidate gene and
selected with G418. Data represent means ± SEM of three inde-
pendent experiments. *p < 0.05, **p < 0.01, ***p < 0.005 versus
iPSCs(Low-K).
(B) Cdh1 and Rex1 mRNA levels in paused iPSC(Low-K) clones that
express each candidate gene after30 days of retrovirus infection.
MEFs were first reprogrammed by SeVdp(fK-OSM) without Shield1
to generate paused iPSC(Low-K) clones, which were then infected
790 Stem Cell Reports j Vol. 8 j 787–801 j March 14, 2017fully reprogrammed iPSCs. Thus, when expressed from the
start of reprogramming, TCL1 not only complements the
low level of KLF4 for full pluripotency, but also appears
to expedite the reprogramming process, suggesting that
TCL1 controls important physiological events that may
otherwise delay or block reprogramming.
KLF4 Directly Regulates Tcl1 Expression in a Dose-
Dependent Manner
When iPSCs(Low-K) transition into iPSCs(High-K), KLF4
upregulates transcription of Tcl1 (Figure 1D). The chro-
matin immunoprecipitation (ChIP) sequencing analyses
in mouse ESCs (Chen et al., 2008) indicate the presence
of two peaks of KLF4 binding, presumably corresponding
to an enhancer (2.6 kb) and the promoter (0.2 kb)
upstream of the Tcl1 transcription start site (Figure 4A).
To confirm whether KLF4 regulates Tcl1 expression
through the putative enhancer and promoter, we con-
structed two reporter plasmids in which the luciferase
gene is driven by both the Tcl1 enhancer and promoter
regions (pL-Tcl1-Luc) or by the promoter region alone
(pS-Tcl1-Luc) (Figure 4A). We used OCT4 as a positive con-
trol for activation of theTcl1 promoter becauseOCT4 binds
and directly upregulates the Tcl1 promoter (Matoba et al.,
2006). As shown in Figure 4B, co-expressed KLF4 increased
pL-Tcl1-Luc by 2.4-fold and pS-Tcl1-Luc by 1.5-fold, indi-
cating that the KLF4 binding sites in both the enhancer
and promoter regions are functional and display additive
effects. In these assays using transiently transfected plas-
mids, however, even overexpressed KLF4 elicited a mere
2.4-fold increase of the Tcl1 reporter gene activity, a
response that is far below the upregulation of the endoge-
nous Tcl1 gene (over 60-fold) when iPSCs(Low-K) transi-
tion into iPSCs(High-K) (Figure 4D). These results raise
the possibility that additional layers of regulatory mecha-
nisms such as epigenetic changes may operate on the
Tcl1 chromatin when KLF4 upregulates the endogenous
Tcl1 gene.
To explore the KLF4-mediated regulation of the endoge-
nous Tcl1 gene, we constructed a Sendai virus vector,with an empty retrovirus or a retrovirus expressing each candidate
gene and selected with G418. Control paused iPSC(Low-K) clones
were not infected with retrovirus but treated with 100 nM
Shield1 to allow them to undergo reprogramming for 30 days.
Data represent means ± SEM of three independent experiments.
**p < 0.01, ***p < 0.005 versus paused iPSC(Low-K) clones in-
fected with an empty retrovirus (Low-K + vector).
(C) Cdh1 and Rex1mRNA levels in MEFs reprogrammed by SeVdp(fK-
OSM) with or without the retrovirus-transduced shRNA against
Tcl1 at day 30. Data represent means ± SEM of three independent
experiments. *p < 0.05.
See also Figure S2 and Table S1.
Figure 3. Expression of TCL1 with the Reprogramming Factors Expedites the Reprogramming Process
(A) Structures of SeVdp(fK-OSM) and its derivative, SeVdp(fKiT-OSM), which expresses TCL1 in addition to the four reprogramming
factors.
(legend continued on next page)
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SeVdp(fKg-OSM), which expresses FLAG-tagged KLF4
fused with the DD (Figure 4C). This vector permits regu-
lation of the KLF4 level by Shield1 and detection of the
chromatin-bound exogenous KLF4 with an anti-FLAG
antibody. SeVdp(fKg-OSM) was similar to SeVdp(fK-OSM)
with respect to both Shield1-mediated regulation of
the KLF4 level (Figures S4A and S4B) and the reprogram-
ming efficiency of MEFs (Figures 4D and S4C). ChIP
analyses of iPSCs(Low-K) and iPSCs(High-K), both of
which were generated with SeVdp(fKg-OSM), revealed
that iPSCs(Low-K) showed little KLF4 binding on both
the Tcl1 enhancer and promoter regions; by contrast,
iPSCs(High-K) showed substantial KLF4 binding at the
enhancer region and, more markedly, on the promoter
region (Figure 4E). Thus, the binding of KLF4 to the
Tcl1 promoter region increases significantly during the
transition from iPSCs(Low-K) into iPSCs(High-K). Despite
the invariable level of OCT4 between iPSCs(Low-K) and
iPSCs(High-K) (Nishimura et al., 2014), the binding of
OCT4 to the Tcl1 promoter region parallels that of KLF4
(Figure 4E), indicating the cooperative binding of KLF4
and OCT4 on the Tcl1 gene.
To analyze if KLF4 and OCT4 bindings alter the epige-
netic status of the Tcl1 promoter region, we performed
ChIP assays for H3K27me3 and H3K4me3, which are
important histone marks that undergo reciprocal changes
during reprogramming (Zhang et al., 2015). The Tcl1
enhancer region had a reduced level of a repressive mark,
H3K27me3, in iPSCs(Low-K) as compared with MEFs (Fig-
ure 4F), while enhancer marks (H3K4me1 and H3K27Ac)
(Creyghton et al., 2010) remained relatively constant.
The Tcl1 promoter region also had a markedly reduced
level of H3K27me3, which appear to have been replaced
by H3K27Ac in iPSCs(Low-K) as compared with MEFs (Fig-
ure 4G, middle and right panels). The levels of H3K4me3,
a mark of active transcription (Zhang et al., 2015), in(B) The KLF4 protein levels from SeVdp(fKiT-OSM). Left panel, western
prepared from MEFs infected for 2 days by either SeVdp(fKiT-OSM) or
without Shield1, respectively. An anti-a-tubulin was used to normaliz
were calculated from the intensity of each band in the blots. Data repre
n.s., not significant.
(C) Expression of pluripotency markers in MEFs infected with the indi
Low-K, respectively) for 21 days. Data represent means ± SEM of thre
(D) Induction of Nanog-GFP by co-expression of TCL1 with the four rep
indicated vector for 11 days, and GFP fluorescence was used to asses
100 mm.
(E) Time course analyses of Nanog-GFP+ colony induction. MEFs were
colonies to that of total colonies was calculated at each indicated da
***p < 0.005 versus SeVdp(KOSM) vector.
(F) Histology of teratomas derived from iPSCs generated with SeVd
immunostaining of SeV NP protein (a). A vector-free clone (clone n
deficiency mice to form teratomas. Teratoma sections stained with H
See also Figure S3 and Table S1.
792 Stem Cell Reports j Vol. 8 j 787–801 j March 14, 2017the Tcl1 promoter region were similarly low in both
MEFs and iPSCs(Low-K). However, iPSCs(High-K) showed
increased H3K4me3 around the Tcl1 transcription start
site (Figure 4G, left panel), probably because of the bind-
ings of KLF4 to the enhancer region (Figure 4E, upper
panel) as well as of KLF4 and OCT4 to the promoter region
(Figure 4E, upper and lower panels). Together, these results
suggest that, during iPSC generation, the Tcl1 gene may
be regulated by two steps; first by OCT4 binding to the
enhancer region, which removes the repressive histone
mark both at the enhancer and promoter regions, and
then by KLF4 binding to the enhancer region, followed
by OCT4 and KLF4 bindings to the promoter, which depo-
sit active histone marks around the transcription start site.
KLF4-Induced TCL1 Activates the AKT Pathway to
Enhance Glycolysis during Reprogramming
A well-recognized function of TCL1 is to bind the AKT
kinase and enhance its activity as a coactivator (Laine
et al., 2000). To dissect the molecular mechanism by
which TCL1 promotes reprogramming, we first analyzed
the roles for AKT during the transition from iPSCs(Low-K)
to iPSCs(High-K). As shown in Figures 5A and 5B, we found
that an active form of AKT, phosphorylated at Ser473, is
increased in iPSCs(High-K) or when exogenous TCL1 was
expressed in iPSCs(Low-K), suggesting that KLF4-induced
TCL1 enhances the AKT activity. A highly selective inhibi-
tor of AKT, MK2206 (Hirai et al., 2010), markedly attenu-
ated the induction of Cdh1 and Rex1 by the increased
KLF4 level or exogenously expressed TCL1 (Figures 5C
and 5D). The attenuated Cdh1 and Rex1 levels were similar
to those observed when the endogenous TCL1 expression
was knocked down by shRNA (Figure 2C). Moreover, an
AKT activator, SC79 (Jo et al., 2012), upregulated Cdh1
but not Rex1, partly recapitulating the effects of the
increased KLF4 level (Figure 5C). Taken together, theseblots to determine the relative KLF4 protein levels. Cell extracts were
SeVdp(fK-OSM). High-K and Low-K indicate MEFs cultured with or
e the sample amounts. Right panel, the relative KLF4 protein levels
sent means ± SEM of three independent experiments. ***p < 0.005.
cated vector and then cultured with or without Shield1 (High-K or
e independent experiments. *p < 0.05, **p < 0.01, ***p < 0.005.
rogramming factors. Nanog-GFP MEFs were reprogrammed with the
s the expression of the Nanog-GFP reporter transgene. Scale bars,
reprogrammed as in (D) and the ratio of the number of Nanog-GFP+
y. Data represent means ± SEM of three independent experiments.
p(fKiT-OSM). Vector removal from iPSC clones was confirmed by
o. 1) was injected subcutaneously into severe combined immuno-
&E showed all three germ layers. Scale bars, 100 mm (b).
(legend on next page)
Stem Cell Reports j Vol. 8 j 787–801 j March 14, 2017 793
Figure 5. TCL1 Upregulates Pluripotency Markers through AKT Activation
(A) Activation of AKT by KLF4 or TCL1. Western blotting was performed using anti-phosphorylated AKT (p-AKT (S473)), anti-AKT, or
anti-a-tubulin antibody for the whole-cell extracts prepared from MEFs, iPSCs(Low-K), iPSCs(High-K), or iPSCs(Low-K) expressing TCL1 at
day 30.
(B) The intensity of each band in (A) was quantified using LAS4000. Data represent means ± SEM of three independent experiments.
*p < 0.05.
(C and D) Cdh1 and Rex1 mRNA levels in MEFs reprogrammed by SeVdp(fK-OSM) with or without Shield1 for 30 days. The cells were treated
only with an inhibitor (1 mM MK2206) or activator (4 mg/mL SC79) of AKT (C), or infected with a TCL1-expressing retrovirus and then
treated with MK2206 (D). Data represent means ± SEM of three independent experiments. *p < 0.05, ***p < 0.005.
See also Figures S5, S6, and S7 and Table S1.data indicate that KLF4-induced TCL1 activates the AKT
pathway, which in turn promotes reprogramming toward
pluripotency.Figure 4. KLF4 Directly Regulates Tcl1 Expression by Binding to I
(A) KLF4 binding on the Tcl1 gene in mouse ESCs is shown by the red
the published ChIP data (Chen et al., 2008). Red lines along the Tcl1 g
indicate the regions amplified in ChIP-qPCR, which overlap with the p
included in the reporter plasmids, pL-Tcl1-Luc and pS-Tcl1-Luc, are a
(B) Luciferase reporter gene assays for the putative regulatory region
with the indicated reporter plasmid (pL-Tcl1-Luc or pS-Tcl1-Luc) and an
SEM of six independent experiments. *p < 0.05, **p < 0.01 versus ME
(C) Structure of SeVdp(fKg-OSM) that expresses FLAG-tagged KLF4 fus
MEFs into iPSCs(Low-K) or iPSCs(High-K) similarly to SeVdp(fK-OSM).
(D) Tcl1 mRNA expression in MEFs infected with vectors expressing DD
or SeVdp(fK-OSM), respectively. SeVdp vector-infected MEFs were re
means ± SEM of three independent experiments. ***p < 0.005.
(E) KLF4 or OCT4 binding to the enhancer, promoter, and gene bod
or iPSCs(High-K) at day 50 using an anti-FLAG or anti-OCT4 antibody. D
0.05.
(F and G) KLF4-dependent alterations in active (H3K4me1, H3K4me3,
the Tcl1 enhancer (F) or promoter region (G). ChIP assays were perfo
MEFs, iPSCs(Low-K), iPSCs(High-K), or mouse ESCs. Data represent mea
***p < 0.005.
See also Figure S4 and Table S1.
794 Stem Cell Reports j Vol. 8 j 787–801 j March 14, 2017Although the AKT pathway is involved in cell pro-
liferation and survival (Manning and Cantley, 2007),
iPSCs(Low-K) and iPSCs(High-K), which differ in AKTts Regulatory Regions
graph created by GeneProf (http://www.geneprof.org), based upon
ene indicate the positions of KLF4 consensus sequences. Gray bars
utative enhancer, promoter, and gene body. The regulatory regions
lso shown at the bottom.
s of the Tcl1 gene. MEFs were collected 2 days after co-transfection
expression plasmid for either KLF4 or OCT4. Data represent means ±
Fs transfected only with the reporter plasmid (control).
ed with the destabilizing domain (DD). SeVdp(fKg-OSM) reprograms
-fused KLF4 with or without the FLAG tag; namely, SeVdp(fKg-OSM)
programmed with or without Shield1 for 14 days. Data represent
y at the Tcl1 locus. ChIP assays were performed for iPSCs(Low-K)
ata represent means ± SEM of three independent experiments. *p <
and H3K27Ac) and repressive (H3K27me3) histone modifications at
rmed using antibodies against indicated histone modifications for
ns ± SEM of three independent experiments. *p < 0.05, **p < 0.01,
(legend on next page)
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activity (Figures 5A and 5B), showed unexpectedly
similar rates of cell proliferation (Figure 6A). We observed,
however, that the media of iPSCs(High-K) turned
yellow faster than that of iPSCs(Low-K) (Figure 6B). This
often indicates lactic acidosis resulting from enhanced
glycolysis, a metabolic state that is reminiscent of the
Warburg effect in cancer. Indeed, both glucose uptake
and lactate production were higher in iPSCs(High-K) than
in iPSCs(Low-K) (Figures 6C and 6D). Moreover, when ex-
pressed in iPSCs(Low-K), exogenous TCL1 elevated glucose
uptake and lactate production to similar levels observed
in iPSCs(High-K) (Figures 6C and 6D). Importantly, an
AKT inhibitor, MK2206, significantly diminished the
enhancement of glucose uptake and almost completely
counteracted the enhancement of lactate production (Fig-
ures 6C and 6D). Retrovirus-mediated expression of TCL1
in paused iPSC(Low-K) clones (Figure S5A) also increased
the phosphorylation of AKT (Figure S5B), which is followed
by the increased glucose uptake and lactate production
(Figure S5C). These metabolic changes concurred with
the increase in Cdh1 expression but preceded the increases
in Fbxo15, Rex1, andNanog expression (Figure S5E). Similar
changes in metabolism and marker gene expression were
observed when Shield1-stabilized KLF4 induced TCL1 in
paused iPSC(Low-K) clones (Figures S5C and S5E). Further-
more, inhibition of AKT by MK2206 in iPSC(High-K)
clones (Figure S6A) diminished glucose uptake and lactate
production (Figure S6B), but did not change the pluripo-
tency marker expression (Figure S6D). These results
demonstrate that KLF4 enhances glycolysis during the
transition from iPSCs(Low-K) to iPSCs(High-K), in large
part through the TCL1-AKT pathway.
Time course analyses of reprogramming of MEFs with
SeVdp(fK-OSM) show that iPSCs(Low-K) display early
increases in glucose uptake and lactate production
by day 4, which remain relatively constant thereafter (Fig-
ure S7A). In addition to these metabolic changes by day 4,
iPSCs(High-K) show further increases in glucose uptake
and lactate production at days 10 and 20, above those of
iPSCs(Low-K) (Figure S7A). These additional metabolicFigure 6. TCL1 Enhances Glycolysis through AKT Activation
(A) Cell growth of iPSCs(Low-K) and iPSCs(High-K). One hundred cells o
cell number was counted every day from day 1. Data represent means
(B) Different colors of the cell culture media of iPSCs(Low-K) and iPS
cultured for 2 days.
(C and D) Glucose uptake (C) or lactate production (D) in iPSCs(
(High-K + MK), iPSCs(Low-K) expressing TCL1 (Low-K + TCL1), or Low
represent means ± SEM of three independent experiments. *p < 0.05
(E) Key proteins in the glycolytic pathway.
(F) The mRNA levels of glycolysis-related genes in the reprogrammed
experiments. *p < 0.05 versus iPSCs(Low-K).
See also Figures S5, S6, and S7 and Table S1.
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concurrent with the increase in Cdh1 expression, and are
followed by increases in Fbxo15, Rex1, and Nanog expres-
sion (Figure S7C).
To identify the genes that the TCL1-AKT pathway regu-
lates to enhance glycolysis, we analyzed five genes that
are critical for the Warburg effect in the glucose meta-
bolism pathway (Figure 6E) (Ito and Suda, 2014). qRT-
PCR showed that the high level of KLF4 or expression
of exogenous TCL1 in iPSCs(Low-K) is accompanied by
increased mRNA expression levels of glucose transporter
(Glut1), pyruvate kinaseM2 (Pkm2), and lactate dehydroge-
nase A (Ldha) (Figure 6F). The increases in the expression
of the three genes were eliminated almost completely by
an AKT inhibitor, MK2206 (Figure 6F). These results show
that KLF4 upregulates Tcl1 expression to enhance the
activity of AKT, which in turn increases expression of key
glycolytic proteins for robust glycolysis.
KLF4-Induced TCL1 Counteracts PnPase to Diminish
Mitochondrial Function
In addition to robust glycolysis, ESCs and iPSCs display
diminished oxidative phosphorylation because they only
possess a small number of immature mitochondria (Buko-
wiecki et al., 2014). We therefore asked if the mitochon-
dria undergo numerical and morphological changes dur-
ing the transition from iPSCs(Low-K) to iPSCs(High-K).
As shown in Figures 7A and 7B, MitoTracker Green stain-
ing of iPSCs(Low-K) and iPSCs(High-K), quantified by
AxioVision, revealed that the mitochondrial content in
iPSCs(High-K) is reduced by more than 60% compared
with that in iPSCs(Low-K). The effect of KLF4 in reducing
the mitochondrial content is mediated by TCL1 because
the mitochondrial reduction was recapitulated by ex-
pressing exogenous TCL1 in iPSCs(Low-K) (Figures 7A
and 7B). However, MK2206 failed to block the effect of
high KLF4 or expression of exogenous TCL1 (Figures 7A
and 7B), showing that KLF4-induced TCL1 reduces the
mitochondrial content independent of the AKT signaling
pathway.f iPSCs(Low-K) or iPSCs(High-K) were passaged to 24-well plate and
± SEM of three independent experiments.
Cs(High-K). 1 3 103 cells of iPSCs(Low-K) and iPSCs(High-K) were
Low-K), iPSCs(High-K), or iPSCs(High-K) with an AKT inhibitor
-K + TCL1 with an AKT inhibitor (Low-K + TCL1+MK) at day 30. Data
, ***p < 0.005.
cells at day 30. Data represent means ± SEM of three independent
Figure 7. TCL1 Suppresses Mitochondrial Function through PnPase
(A) Mitochondrial contents were visualized by staining cells with MitoTracker Green FM at day 30. The stained cells were iPSCs(Low-K),
iPSCs(High-K), or iPSCs(Low-K) expressing TCL1 with or without an AKT inhibitor (MK). Scale bars, 10 mm.
(B) Fluorescence intensities in (A) were quantified using AxioVision software. Data represent means ± SEM of at least three independent
experiments. ***p < 0.005 versus iPSCs(Low-K).
(C) Mitochondrial contents were visualized as in (A), but retrovirus-mediated expression of PNPT1 was performed instead of treating with
MK. Scale bars, 10 mm.
(D) Fluorescence intensities in (C) were quantified as in (B). **p < 0.01, ***p < 0.005.
(E) Oxygen consumption in the same set of reprogrammed cells as in (C). Data represent means ± SEM of three independent experiments.
***p < 0.005.
(F) Cdh1 and Rex1 mRNA levels in the same set of reprogrammed cells as in (C). Data represent means ± SEM of three independent ex-
periments. *p < 0.05, **p < 0.01, ***p < 0.005.
(G) Schematic model summarizing the role for KLF4 in promoting the metabolic shift through TCL1.
See also Figures S5, S6, and S7 and Table S1.
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Recent studies show that, in addition to functioning
as a coactivator of AKT, TCL1 interacts directly with
mitochondrial PnPase to inhibit mitochondrial biogen-
esis and oxidative phosphorylation (Khaw et al., 2015).
PnPase, encoded by the Pnpt1 gene, is localized in the
mitochondrial inner membrane space and facilitates
RNA import into mitochondria, thereby maintaining
the mitochondrial content and their homeostasis by an
as-yet-unknown mechanism (Wang et al., 2010). To
find if the KLF4-TCL1 pathway directly reduces the
mitochondrial content by counteracting PnPase, we
investigated the role for PnPase in KLF4-induced mito-
chondrial reduction. Expression of exogenous PnPase
in iPSCs(High-K) or TCL1-expressing iPSCs(Low-K)
almost completely prevented the reduction of the mito-
chondrial content by high KLF4 or exogenous TCL1
(Figures 7C and 7D). Thus, PnPase antagonizes the
effect of high KLF4 and exogenous TCL1, in congruent
with the direct physical association and functional
antagonism between TCL1 and PnPase (Khaw et al.,
2015). Analyses of oxygen consumption, which reflects
the mitochondrial respiration, also confirmed the antag-
onism between the KLF4-TCL1 pathway and PnPase,
indicating that TCL1 reduces mitochondrial content
and function by counteracting PnPase (Figure 7E),
presumably through direct physical interaction with
PnPase. Moreover, the expression of exogenous PnPase
in iPSCs(High-K) or TCL1-expressing iPSCs(Low-K)
decreased the expression of Cdh1 and Rex1 (Figure 7F),
suggesting that the increased mitochondrial content by
itself may negatively impact the KLF4-induced progres-
sion of reprogramming.
To further confirm the above findings, we tested the
effect of increased KLF4 and exogenous TCL1 in paused
iPSC(Low-K) clones (Figure S5A). Restoration of the
KLF4 level and retrovirus-mediated expression of TCL1
in paused iPSC(Low-K) clones diminished the mitochon-
drial content and oxygen consumption (Figure S5D) and
increased Cdh1 expression, which was followed by the
increased expression of Fbxo15, Rex1, and Nanog (Fig-
ure S5E). Furthermore, expression of PnPase, but not
inhibition of AKT by MK2206, in iPSC(High-K) clones
(Figure S6A) increased the mitochondrial content and
oxygen consumption (Figure S6C). However, the expres-
sion of PnPase did not affect glucose uptake and lactate
production (Figure S6B). Time course analyses of re-
programming (Figure S7) also indicate that reduction of
the mitochondrial content and oxygen consumption
(Figure S7B) parallel the increases in glucose uptake and
lactate production (Figure S7A). Taken together, our re-
sults indicate that, besides enhancing glycolysis via
AKT activation, KLF4-induced TCL1 diminishes oxidative
phosphorylation through antagonizing PnPase to pro-798 Stem Cell Reports j Vol. 8 j 787–801 j March 14, 2017mote the metabolic shift during reprogramming toward
full pluripotency (Figure 7G).DISCUSSION
We found here that Tcl1 is one of the important direct tar-
gets of KLF4 and KLF4-induced TCL1 directs a metabolic
shift during reprogramming by both enhancing glycolysis
and diminishing oxidative phosphorylation. Our analyses
revealed that KLF4 regulates TCL1 expression at the level
of transcription by directly binding the Tcl1 enhancer
and promoter when cells transition from iPSCs(Low-K) to
iPSCs(High-K), simultaneously recruiting OCT4 to the
Tcl1 promoter. The increased binding of KLF4 and OCT4
is accompanied by deposition of H3K4me3 at the Tcl1 pro-
moter, which has already lost H3K27me3 and acquired
H3K27Ac before the transition (Figures 4E and 4G). Given
that the 3-fold increase of the KLF4 permits the deposition
of H3K4me3, there may be a critical threshold for deposi-
tion of each histone mark. Moreover, because subsets of
genes increase expression at a distinct stage of reprogram-
ming (Nishimura et al., 2014), the critical threshold during
reprogramming may differ for individual genes.
Rapidly proliferating cells have a high demand for
essential cell components, which is met by increased
glycolysis that shunts the metabolic intermediates toward
synthesis of building blocks for nucleic acids, lipids, and
proteins (Vander Heiden et al., 2009). This is achieved
by aerobic glycolysis, also known as the Warburg effect,
which has recently been acknowledged as an important
metabolic state in cancer cells (Courtnay et al., 2015),
adult stem cells as well as ESCs (Ito and Suda, 2014). In
cancer cells, central to aerobic glycolysis is the phos-
phatidylinositol 3-kinase-AKT-mammalian target of the
rapamycin signaling pathway and the hypoxia-inducible
factor 1a (HIF1a) pathway, which regulate cell prolifera-
tion, survival, and metabolism (Courtnay et al., 2015).
In adult stem cells, the same pathways also play an essen-
tial role for maintaining aerobic glycolysis in hypoxic
stem cell niches (Ito and Suda, 2014). ESCs also display
aerobic glycolysis and reduced oxidative phosphorylation,
and the AKT pathway is an important downstream target
of leukemia inhibitory factor (LIF), which is essential for
self-renewal and pluripotency of ESCs (Niwa et al.,
2009). However, the role for the AKT pathway in the
metabolic state of ESCs is less clear.
Our results indicate that Tcl1 regulates AKT to enhance
glycolysis and inhibits PnPase to diminish oxidative phos-
phorylation in fully reprogrammed iPSCs, and perhaps in
ESCs as well. Although ESCs express a high level of Tcl1
(Miyazaki et al., 2013), its role as a metabolic regulator
in ESCs remains undefined. Further contributing to this
uncertainty is the fact that only a slight decrease in cell
proliferation is observed in Tcl1(/) ESCs, without any
change in the phosphorylated form of AKT (Miyazaki
et al., 2013). Tcl1(/) embryos, however, show a more
unambiguous phenotype, displaying a defect in early
embryonic development (Narducci et al., 2002). Given
that TCL1 is not the mainstream pathway that connects
to AKT but merely modulates its activities, augmentation
of the AKT activities via LIF in cell culture medium, for
instance, may compensate for the lack of Tcl1 in ESCs
cultured in vitro. Its requirement, however, may be more
stringent in the developing embryo, where such signals
could be less variable.
Regardless of the detailed mechanisms of metabolic
regulation in ESCs, recent studies indicate that reprogram-
ming MEFs into iPSCs involves dramatic changes in cell
metabolism from oxidative phosphorylation to glycolysis
(Folmes et al., 2011). Somewhat paradoxically, however,
the early phase of the metabolic shift involves a burst in
oxidative phosphorylation (Hawkins et al., 2016; Kida
et al., 2015), which is mediated by estrogen-related recep-
tors, when cell proliferation increases dramatically (Kida
et al., 2015). This burst in oxidative phosphorylation gener-
ates reactive oxygen species (ROS), which in turn leads to
the increased expressionof nuclear factor erythroid-derived
2-like 2, nuclear factor kB, and AP-1, eventually increasing
the level of HIF1a. Sequential activation of these transcrip-
tion factors gradually diminishes oxidative phosphoryla-
tion and enhances glycolysis (Hawkins et al., 2016).
The metabolic shift elicited by KLF4-induced TCL1 dur-
ing the transition from iPSCs(Low-K) to iPSCs(High-K) is
probably distinct from, and preceded by, the ROS-induced
changes in metabolism (Hawkins et al., 2016; Kida et al.,
2015). Indeed, no difference in the cell proliferation rate
was observed between iPSCs(Low-K) and iPSCs(High-K).
Moreover, the protein level of HIF1a, which is regulated
by proteolysis (Courtnay et al., 2015), and themRNA levels
of Pdk1 and Hk2, which are regulated by HIF1a (Semenza,
2010), remain essentially unchanged during this transition
(Figure 6F and data not shown). Thus, the metabolic shift
may involve a series of events, consisting of at least two
phases, and cells respond appropriately to the ongoing
metabolic demand in each phase of reprogramming.
Notably, the latter metabolic shift probably initiates
slightly earlier but largely concurs with the acquisition of
full pluripotency when the metabolism in reprogrammed
cells becomes indistinguishable from that of ESCs.
In this article, we revealed that one of the key functions
of KLF4-induced TCL1 during reprogramming is to pro-
mote the metabolic shift from oxidative phosphorylation
to glycolysis. Despite its role in a late stage of reprogram-
ming, expression of TCL1 with the four reprogramming
factors from the beginning of reprogramming results infaster and higher induction of pluripotency markers (Fig-
ures 3C–3E). Indeed, TCL1b1, another member of the
TCL family (Hallas et al., 1999), also improves the effi-
ciency of reprogramming (Khaw et al., 2015). Given that
the metabolic shift in the earlier stage occurs via ROS pro-
duction (Hawkins et al., 2016), it is tempting to hypothe-
size that expression of TCL1 throughout reprogramming
may permit cells with lower ROS production to undergo
the metabolic shift. This might minimize the exposure of
cells to ROS during reprogramming, potentially reducing
damage to the genome in the generated iPSCs.EXPERIMENTAL PROCEDURES
Cell Culture and Generation of iPS Cells
Mouse iPSCs were generated from MEFs isolated from trans-
genic mice carrying the Nanog-GFP-IRES-Puro reporter construct
(Okita et al., 2007) (provided by the RIKEN BioResource Center)
(Nanog-GFP MEFs) by infection with an indicated SeVdp vector at
32C for 14 hr. The infected cells were seeded onto mitomycin
C-treated neomycin-resistant SNL76/7 feeder cells and grown in
KSR medium (KnockOut DMEM [Thermo Fisher] supplemented
with 15% KnockOut Serum Replacement [Thermo Fisher], 2 mM
GlutaMAX [Thermo Fisher], 0.1 mM non-essential amino acids
[Thermo Fisher], 55 mM 2-mercaptoethanol [Thermo Fisher],
100 U/mL penicillin-streptomycin [Wako], and 1,000 U/mL LIF
[Wako]) for 7days, afterwhich themediumwas replacedbymESme-
dium (DMEM[Nacalai Tesque] supplementedwith15% fetal bovine
serum [HyClone], 0.1 mMnon-essential amino acids, 55 mM2-mer-
captoethanol, 100 U/mL penicillin-streptomycin, and 1,000 U/mL
LIF), in the presence or absence of 100 nM Shield1 (Takara Bio).
Nanog-GFP MEFs or iPSCs(Low-K) were infected with the indi-
cated retrovirus for 2 days with 8 mg/mL hexadimethrine bromide
(polybrene; Sigma). The cells were then used for iPSC generation
or passaged onto feeder cells, respectively, with 800 mg/mL G418
(Nacalai Tesque) and/or 2 mg/mL puromycin (Nakalai Tesque) for
selection of retroviral vector-infected cells.
Teratoma Formation
Animal experiments were carried out in accordance with the pro-
tocols approved by University of Tsukuba Ethics Committee for
Animal Experiments. Teratomawas formed by subcutaneous injec-
tion of 1 3 106 iPSCs, generated by SeVdp(fKiT-OSM), into SCID
mice. After 4 weeks, tumors were harvested at necropsy, fixed over-
night in 4% paraformaldehyde in PBS, and embedded in paraffin
wax. The tumor samples were sectioned at 4 mm and stained
withH&E.Histological findingswere evaluated using amicroscope
BX50 (Olympus) equipped with a digital camera G11 (Canon).
Determination of Glucose Uptake
Cells (5.0 3 105), cultured in KSR medium without feeder cells,
were treated with 1mM2-deoxy-D-glucose (2DG) (Nacalai Tesque)
for 20 min at 37C, followed by washing with PBS plus 0.2 mM
Phloretin (Tokyo Chemical Industry). 2DG in the cells was
determined using a 2DG Uptake Measurement Kit (Cosmo Bio)
according to manufacturer’s procedures.Stem Cell Reports j Vol. 8 j 787–801 j March 14, 2017 799
Determination of Lactate Production
Cells (2.03 105) were cultured in KSRmediumwith feeder cells for
6 hr, and the cell culture mediumwas collected and centrifuged to
remove cells. The amount of lactate in the medium was deter-
mined using a Glycolysis Cell-Based Assay Kit (Cayman Chemical)
according to the manufacturer’s procedures.
Mitochondrial Staining
Cells were treated with 20 nM MitoTraker Green FM (Molecular
Probes) for 30 min at 37C. To determine the presence of mito-
chondria, cells were observed under Axio Observer fluorescent
microscopy (Zeiss), and the strength of the GFP signal was deter-
mined using AxioVision software (Zeiss).
Determination of Oxygen Consumption
Cells (1.0 3 105) were cultured in a 96-well plate with feeder cells
for 1 day, and the extracellular oxygen consumption was deter-
mined using an Extracellular Oxygen Consumption Assay Kit
(Abcam) according to the manufacturer’s procedures.
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